Parabilis Medicines Posts $2.32 Q2 Loss Per Share
PBLS sits 53% above its 52-week low of $24.51 on light trading volume (0.3× avg).
Summary
Parabilis Medicines reported a Q2 loss of $2.32 per share, the first earnings disclosure since its June IPO. The company priced its upsized offering at $20 per share and raised $770.5 million, with RA Capital Management holding a 23.8% stake. The loss is significant relative to the $37.41 stock price, but no revenue or guidance figures were provided. The company also provided business updates in its second quarter 2026 financial results.
At the time of this announcement, PBLS was trading at $37.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $24.51 to $37.83. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.